PBMT-GEN-031
ADMINISTRATION OF MYCOPHENOLATE MOFETIL (CELLCEPT)

1 PURPOSE
1.1 To outline the procedure required for administration of mycophenolate mofetil (CellCept). Responsibilities of the nursing staff for administering and monitoring adverse reactions to mycophenolate mofetil are described.

2 INTRODUCTION
2.1 Mycophenolate mofetil (CellCept) is a medication used to decrease the immune response and prevent rejection in patients who receive organ or bone marrow transplants.
2.2 This medication can be given by the intravenous (IV) or oral (PO) route.

3 SCOPE AND RESPONSIBILITIES
3.1 Interdisciplinary: Requires an order by a physician or designee in the electronic medical record.
3.2 Registered Nurses (RNs) may administer mycophenolate mofetil after successful completion of the medication administration test and demonstration of clinical competency with their preceptor.

4 DEFINITIONS/ACRONYMS
4.1 GI Gastrointestinal
4.2 IV Intravenous
4.3 PO Oral
4.4 RN Registered Nurse

5 MATERIALS
5.1 Primed primary IV administration set.
  5.1.1 CellCept is prepared by pharmacy for infusion.
  5.1.2 Alcohol prep pad.
  5.1.3 Gloves (non-sterile)
  5.1.4 Secondary tubing if medication arrives in bag

6 EQUIPMENT
6.1 Medication administration line.
6.2 Volumetric or Syringe Pump.
7 SAFETY
7.1 N/A

8 PROCEDURE
8.1 Patient Assessment:
8.1.1 Assess IV for patency.
8.2 Administration:
8.2.1 Mycophenolate mofetil is to be prepared by pharmacy.
8.2.2 If Administered IV:
8.2.2.1 Spike the medication bag on secondary tubing and attach to primary IV set.
8.2.2.2 Attach the medication syringe to primary syringe pump tubing.
8.2.2.3 Begin the infusion as ordered. Mycophenolate mofetil is administered IV over 2 hours or as written in the medication order.
8.2.2.4 Notify the physician or designee of any side effects, including, but not limited to, hypotension, temperature greater than (> 38.5 degrees C, hives, chills, and anaphylaxis.
8.2.2.5 Upon completion of infusion, set pump for the normal saline infusion or D5W flush, as applicable, to insure entire dose has infused.
8.2.3 If administered enteral via tube:
8.2.3.1 Ensure tube is flushed before and after administration.
8.3 Side effects:
8.3.1 The most common side effects associated with Mycophenolate mofetil therapy involve the gastrointestinal (GI) tract, especially diarrhea and vomiting. The reported GI adverse effects occur in greater than (> 10% of patients and include:
8.3.1.1 nausea/vomiting
8.3.1.2 soft stools and/or diarrhea
8.3.1.3 flatulence
8.3.1.4 abdominal pain
8.3.1.5 constipation
8.3.1.6 dyspepsia
8.3.1.7 oral candidiasis
8.3.1.8 anorexia
8.3.1.9 GI bleeding including peptic ulcer or other GI ulceration and GI perforation
8.3.1.10 Colitis, sometimes caused by cytomegalovirus, ischemic colitis, and pancreatitis have been reported

8.3.2 Other adverse effects include:
8.3.2.1 generalized pain
8.3.2.2 fever
8.3.2.3 headaches
8.3.2.4 asthenia
8.3.2.5 chest pain
8.3.2.6 elevated hepatic enzymes
8.3.2.7 thrombocytopenia
8.3.2.8 red cell aplasia
8.3.2.9 immunosuppression
8.3.2.10 agranulocytosis
8.3.2.11 back pain
8.3.2.12 hypertension
8.3.2.13 hypotension
8.3.2.14 tachycardia
8.3.2.15 edema
8.3.2.16 hematuria
8.3.2.17 hypercholesterolemia
8.3.2.18 hypokalemia
8.3.2.19 hyperkalemia
8.3.2.20 hyperglycemia
8.3.2.21 hypophosphatemia
8.3.2.22 dyspnea
8.3.2.23 pharyngitis
8.3.2.24 acneiform rash
8.3.2.25 renal tubular necrosis
8.3.2.26 tremor
8.3.2.27 insomnia
8.3.2.28 sepsis
8.3.2.29 dizziness

9 RELATED FORMS

9.1 NA

10 REFERENCES

10.1 2007 THOMPSON MICROMEDEX

11 REVISION HISTORY

<table>
<thead>
<tr>
<th>Revision No.</th>
<th>Author</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>06</td>
<td>S. McCollum</td>
<td>Side effects moved from Introduction Section to Procedure Section (section 8.3) for better flow of document.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Side effect list updated to include effects on cell counts.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Infusion duration of 2 hours moved from Patient Assessment Section to Administration Section (section 8.2.4) for better flow of document.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acronyms defined throughout.</td>
</tr>
</tbody>
</table>
### PBMT-GEN-031 Administration of Mycophenolate Mofetil Cellcept

#### Author

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally McCollum</td>
<td></td>
<td>07 Nov 2018, 10:46:29 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Medical Director

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Kurtzberg</td>
<td></td>
<td>07 Nov 2018, 12:15:36 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Quality

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bing Shen</td>
<td></td>
<td>08 Nov 2018, 11:58:32 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Document Release

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Jordan</td>
<td></td>
<td>09 Nov 2018, 11:12:40 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>